Portal Hypertension - Pipeline Review, H2 2016

Published: Aug, 2016 | Pages: 69 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Portal Hypertension - Pipeline Review, H2 2016

Summary

Global Markets Direct's, 'Portal Hypertension - Pipeline Review, H2 2016', provides an overview of the Portal Hypertension pipeline landscape. 

The report provides comprehensive information on the therapeutics under development for Portal Hypertension, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Portal Hypertension and features dormant and discontinued projects. 

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Portal Hypertension
- The report reviews pipeline therapeutics for Portal Hypertension by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved Portal Hypertension therapeutics and enlists all their major and minor projects
- The report assesses Portal Hypertension therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Portal Hypertension

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Portal Hypertension
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Portal Hypertension pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Portal Hypertension Overview 6
Therapeutics Development 7
Pipeline Products for Portal Hypertension - Overview 7
Portal Hypertension - Therapeutics under Development by Companies 8
Portal Hypertension - Pipeline Products Glance 9
Clinical Stage Products 9
Early Stage Products 10
Portal Hypertension - Products under Development by Companies 11
Portal Hypertension - Companies Involved in Therapeutics Development 12
Conatus Pharmaceuticals Inc. 12
Cumberland Pharmaceuticals, Inc. 13
Galectin Therapeutics, Inc. 14
Genextra S.p.a. 15
LinXis B.V. 16
Mezzion Pharma Co. Ltd. 17
Portal Hypertension - Therapeutics Assessment 18
Assessment by Monotherapy Products 18
Assessment by Target 19
Assessment by Mechanism of Action 21
Assessment by Route of Administration 23
Assessment by Molecule Type 25
Drug Profiles 27
emricasan - Drug Profile 27
Product Description 27
Mechanism Of Action 27
R&D Progress 27
GRMD-02 - Drug Profile 33
Product Description 33
Mechanism Of Action 33
R&D Progress 33
ifetroban sodium - Drug Profile 44
Product Description 44
Mechanism Of Action 44
R&D Progress 44
LIN-003 - Drug Profile 46
Product Description 46
Mechanism Of Action 46
R&D Progress 46
obeticholic acid - Drug Profile 47
Product Description 47
Mechanism Of Action 47
R&D Progress 47
udenafil - Drug Profile 57
Product Description 57
Mechanism Of Action 57
R&D Progress 57
Portal Hypertension - Dormant Projects 60
Portal Hypertension - Discontinued Products 61
Portal Hypertension - Product Development Milestones 62
Featured News & Press Releases 62
Oct 20, 2015: Conatus Pharmaceuticals Announces Acceptance of Late-Breaking Abstract for AASLD Annual Meeting 62
ep 23, 2015: Conatus Announces Top-line Results From Multicenter Phase 2 Portal Hypertension Clinical Trial in Patients With Liver Cirrhosis 62
Nov 10, 2014: Conatus Pharmaceuticals Presents Late-Breaking Poster At AASLD Annual Meeting 64
Oct 08, 2014: Conatus Pharmaceuticals Announces Acceptance Of Late-Breaking Abstract For AASLD Annual Meeting 65
Sep 02, 2014: Conatus Pharmaceuticals Initiates Phase 2 Trial in Patients with Liver Cirrhosis and Separate Open Label Phase 2 Trial in Cirrhosis Patients with Portal Hypertension 65
Nov 08, 2012: Intercept Pharma To Present Phase IIa Portal Hypertension Data At AASLD's Annual Liver Meeting 66
Appendix 68
Methodology 68
Coverage 68
Secondary Research 68
Primary Research 68
Expert Panel Validation 68
Contact Us 68
Disclaimer 69

List of Tables

Number of Products under Development for Portal Hypertension, H2 2016 7
Number of Products under Development by Companies, H2 2016 8
Comparative Analysis by Clinical Stage Development, H2 2016 9
Comparative Analysis by Early Stage Development, H2 2016 10
Products under Development by Companies, H2 2016 11
Portal Hypertension - Pipeline by Conatus Pharmaceuticals Inc., H2 2016 12
Portal Hypertension - Pipeline by Cumberland Pharmaceuticals, Inc., H2 2016 13
Portal Hypertension - Pipeline by Galectin Therapeutics, Inc., H2 2016 14
Portal Hypertension - Pipeline by Genextra S.p.a., H2 2016 15
Portal Hypertension - Pipeline by LinXis B.V., H2 2016 16
Portal Hypertension - Pipeline by Mezzion Pharma Co. Ltd., H2 2016 17
Assessment by Monotherapy Products, H2 2016 18
Number of Products by Stage and Target, H2 2016 20
Number of Products by Stage and Mechanism of Action, H2 2016 22
Number of Products by Stage and Route of Administration, H2 2016 24
Number of Products by Stage and Molecule Type, H2 2016 26
Portal Hypertension - Dormant Projects, H2 2016 60
Portal Hypertension - Discontinued Products, H2 2016 61